brusatol has been researched along with Experimental Hepatoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, N; Guo, P; He, Q; Hong, Z; Xiang, Y; Ye, R; Zhang, Q | 1 |
1 other study(ies) available for brusatol and Experimental Hepatoma
| Article | Year |
|---|---|
Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quassins; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |